Public release date: 27-Jun-2012 [ | E-mail | Share ] <\/p>\n
Contact: Kevin Korpics kevin@engconfintl.org<\/a> Engineering Conferences International<\/p>\n Oligonucleotide technologies, such as siRNA, tap into endogenous, highly conserved and specific catalytic mechanisms to efficiently regulate gene expression. As such, they have the potential to enable the development of novel therapeutic options for disease targets previously considered un-druggable by conventional small molecule and biologics means. However, despite the promise, clinical development has been hindered by the challenges encountered by identifying and developing safe and efficacious delivery formulations. <\/p>\n Since its discovery in 1998, RNA silencing has attracted much attention, with over 50,000 peer-reviewed publications, multiple national and international conferences, and significant investment in the biotech and large pharma with the goal of developing new siRNA-based therapies. Despite the interest and investment this has proven to be more difficult that first envisioned. It is widely recognized that there are gaps in our basic understanding on how to best harness this technology for therapeutic use. <\/p>\n The major topics to be discussed are: <\/p>\n Liposomes, nanosomes, polymeric and nano-particulate delivery vehicles RNA chemical modifications and conjugates to enable delivery Protein transduction domain as delivery platforms Mechanisms of cellular uptake and endosomal escape Biophysical characterization methods siRNA delivery vehicle toxicology Local and systemic siRNA delivery case studies <\/p>\n Confirmed Speakers Achim Aigner, Philipps-University Marburg, Germany Saghir Akhtar, Kuwait University, Kuwait Eben Alsberg, Case Western Reserve University, USA Dan Anderson, MIT, USA Tomohiro Asai, University of Shizuoka, Japan Himanshu Brahmbhatt, EnGeneIC Ltd, Australia Bob Brown, Dicerna, USA Kenneth Clark, GlaxoSmithKline, UK Pieter Cullis, University of British Columbia, Canada Mark E. Davis, California Institute of Technology, USA Derek M. Dykxhoorm, University of Miami Miller School of Medicine, USA Xavier de Mollerat Du Jeu, Life Technologies, USA Omid Farokhzad, Harvard Medical School, USA Elena Feinstein, Quark Pharma, Israel \/ USA Mauro Ferrari, The Methodist Hospital Research Institute, USA Mercedes Gonzlez-Juarrero, Colorado State University, USA Tatsuhiro Ishida, The University of Tokushima, Japan Rudy Juliano, University of North Carolina Chapel Hill, USA Jan Kamps, University of Groningen, The Netherlands Kazunori Kataoka, University of Tokyo, Japan Jrgen Kjems, rhus University, Denmark Troels Koch, Santaris Pharma A\/S, Denmark \/ USA lo Langel, Stockholm University, Sweden Gabriel Lpez-Berestein, The University of Texas MD Anderson Cancer Center, USA Zheng-Rong Lu, Case Western Reserve University, USA Jennifer MacDiarmid, EnGeneIC Ltd, Australia Ram I. Mahato, University of Tennessee Health Science Center, USA Muthiah Manoharan, Alnylam Pharmaceuticals, USA Nigel A.J. McMillan, Diamantina Institute, University of Queensland, Australia X in Ming, University of North Carolina Chapel Hill, USA Tamara Minko, Rutgers University, USA Andrs Montefeltro, nLife Therapeutics, Spain Sterghios Moschos, University of Westminster, UK Deborah Palliser, Albert Einstein School of Medicine, USA Dan Peer, Tel Aviv University, Israel Jean Phillipe Pellois, Texas A&M University, USA Blake Peterson, The University of Kansas, USA Tariq M. Rana, Sanford-Burnham Medical Research Institute, USA Steven L. Regen, Lehigh University, USA John Rossi, City of Hope, Duarte, USA Dmitry Samarsky, RiboBio, China Ansgar Santel, Silence Therapeutics AG, Germany Alan D. Schreiber, ZaBeCor Pharmaceuticals, Inc., USA Sabine Schreidler, Sanofi-Aventis, Germany Georg Sczakiel, University of Lbeck, Germany Peter H. Seeberger, Max Planck Institute of Colloids and Interfaces, Berlin, Germany Rita Serda, Methodist Hospital Research Institute, USA Mouldy Sioud, Norwegian Radium Hospital, Norway Anil Sood, MD Anderson Cancer Center, USA Janos Szebeni, Semmelweis University, Budapest, Hungary C. Shad Thaxton, Northwestern University, USA Ernst Wagner, Ludwig-Maximilians-Universitat, Munchen, Germany Roberto Weinmann, Sylentis, Spain Johannes Winkler, University of Vienna, Austria You-Yeon Won, Purdue University, USA Matthew Wood, Oxford University, UK Miqin Zhang, University of Washington, USA <\/p>\n ### <\/p>\n Submission of Abstracts <\/p>\n ABSTRACT SUBMISSION IS NOW OPEN <\/p>\n<\/p>\n The rest is here: Public release date: 27-Jun-2012 [ | E-mail | Share ] Contact: Kevin Korpics kevin@engconfintl.org<\/a> Engineering Conferences International Oligonucleotide technologies, such as siRNA, tap into endogenous, highly conserved and specific catalytic mechanisms to efficiently regulate gene expression. As such, they have the potential to enable the development of novel therapeutic options for disease targets previously considered un-druggable by conventional small molecule and biologics means Continue reading
\nOligonucleotide Delivery: Biology, Engineering and Development Conference<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"